Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 20/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.53 |
| ▸ | OXTR | P30559 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3330501 | 0.99 | AVPR1A (0.57) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL7909085 | 0.91 | AVPR1A (0.62) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL11941018 | 0.91 | AVPR1A (0.62) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL11934662 | 0.91 | AVPR1A (0.62) | AVPR1AKCNH2AVPR2OXTR | |
| Hydrochloric Acid SCHEMBL3333965 | 0.90 | AVPR1A (0.61) | AVPR1AKCNH2AVPR2OXTR | |
| Hydrochloric Acid SCHEMBL3331435 | 0.90 | AVPR1A (0.61) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL11934664 | 0.90 | AVPR1A (0.58) | AVPR1AKCNH2AVPR2OXTR | |
| Hydrochloric Acid SCHEMBL3330654 | 0.89 | AVPR1A (0.58) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL7905370 | 0.87 | AVPR1A (0.57) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL15234201 | 0.87 | AVPR1A (0.57) | AVPR1AKCNH2AVPR2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461152-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461152-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | SCHNIDER PATRICK (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | SCHNIDER PATRICK (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8227458-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227458-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2010060836-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-03 | — | — | WO | disclosed |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN-LA ROCHE, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN-LA ROCHE, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885KCNH2 490/4885AVPR2 3/4885 |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885KCNH2 490/4885AVPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.